|
KMID : 1040620220280040890
|
|
Clinical and Molecular Hepatology
2022 Volume.28 No. 4 p.890 ~ p.911
|
|
|
COVID-19 vaccine immunogenicity among chronic liver disease patients and liver transplant recipients: A meta-analysis
|
|
Cheung Ka Shing
Mok Chiu Hang
Mao Xianhua
Zhang Ruiqi R.
Hung Ivan F. N.
Seto Wai Kay
Yuen Man Fung
|
|
|
Abstract
|
|
|
Background/Aims: Data of coronavirus disease 2019 (COVID-19) vaccine immunogenicity among chronic liver disease (CLD) and liver transplant (LT) patients are conflicting. We performed meta-analysis to examine vaccine immunogenicity regarding etiology, cirrhosis status, vaccine platform and type of antibody.
Methods: We collected data via three databases from inception to February 16, 2022, and reported pooled seroconversion rate, T cell response and safety data after two vaccine doses.
Results: Twenty-eight (CLD only: 5; LT only: 18; both: 2; LT with third dose: 3) observational studies of 3,945 patients were included. For CLD patients, seroconversion rate ranged between 84% (95% confidence interval [CI], 76?90%) and 91% (95% CI, 83?95%), based predominantly on neutralizing antibody and anti-spike antibody, respectively. Seroconversion rate was 81% (95% CI, 76?86%) in chronic hepatitis B, 96% (95% CI, 93?97%) in non-alcoholic fatty liver disease, 85% (95% CI, 75?91%) in cirrhosis and 85% (95% CI, 78?90%) in non-cirrhosis, 86% (95% CI, 78?92%) for inactivated vaccine and 89% (95% CI, 71?96%) for mRNA vaccine. The pooled seroconversion rate of anti-spike antibody was 66% (95% CI, 55?75%) after two doses of mRNA vaccines and 88% (95% CI, 58?98%) after third dose among LT recipients. T cell response rate was 65% (95% CI, 30?89%). Prevalence of adverse events was 27% (95% CI, 18?38%) and 63% (95% CI, 39?82%) among CLD and LT groups, respectively.
Conclusions: CLD patients had good humoral response to COVID-19 vaccine, while LT recipients had lower response.
|
|
|
KEYWORD
|
|
|
COVID-19, SARS-CoV-2, Liver transplant, Chronic hepatitis B, Non-alcoholic fatty liver disease
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
    
|
|